Saturday 31 October 2026
Export LLY’s income statement to Excel — free account
Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
1,415.16
41.46
+3.02%
Follow LLY
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
9 | 8 | 7 | 8 |
+8 more TTM periods Free account |
| 102.29% | 107.46% | 101.16% | 96.47% | ||
| 21.97% | 24.54% | 21.59% | 19.33% | ||
ROIC |
26.33% | 30.18% | 26.61% | 25.82% | |
Return on Tangible Assets |
57.79% | 56.50% | 45.79% | 41.61% | |
Average Days of Receivables |
107.56 | 106.99 | 112.87 | 119.52 | |
Free Cash Flow per Share |
20.38 | 13.22 | 10.00 | 10.34 | |
Free Cash Flow |
18,190.00 | 11,823.00 | 8,972.00 | 9,271.80 | |
Capital Expenditures |
(9,893.00) | (8,657.00) | (7,841.00) | (6,790.50) | |
| Other line items | |||||
Cash ROIC |
18.61% | 15.59% | 11.76% | 12.42% | |
Accounts Receivable Turnover |
3.92 | 4.11 | 3.90 | 3.77 | |
Accounts Payable Turnover |
2.60 | 2.93 | 2.57 | 2.82 | |
Inventory Turnover |
0.95 | 1.04 | 1.04 | 1.03 | |
Average Days of Payables |
168.70 | 147.98 | 177.65 | 154.26 | |
Days of Inventory on Hand |
463.51 | 427.53 | 453.91 | 440.85 | |
Tax Rate |
(0.20) | (0.19) | (0.20) | (0.18) | |
Research and Development Expense of Revenue |
18.32% | 19.53% | 20.46% | 21.13% | |
Selling, General and Administrative Expense of Revenue |
15.36% | 16.00% | 17.02% | 17.48% | |
Share Based Compensation of Revenue |
0.81% | 0.88% | 0.96% | 1.06% | |
Interest Coverage |
83.46 | — | — | — | |
Operating CF/Net income |
1.05 | 0.81 | 0.81 | 0.87 | |
Depreciation/Fixed assets |
0.07 | 0.08 | 0.08 | 0.09 | |
Capex/Depreciation |
(4.71) | (4.24) | (3.93) | (3.58) | |
Revenue per Share |
89.27 | 80.77 | 72.64 | 66.25 | |
Operating CF per Share |
31.47 | 22.90 | 18.74 | 17.91 | |
Capex per Share |
(11.09) | (9.68) | (8.74) | (7.57) | |
Capex to Sales |
0.12 | 0.12 | 0.12 | 0.11 |
Columns are period end dates